Although KRASG12C-specific inhibitors, such as sotorasib and adagrasib, have been encouraged in recent years because of the success of drugging ‘undruggable’ targets [2–4], various treatment approaches tested for KRAS-mutant cancers, excluding NSCLC with the KRASG12C mutation, have not achieved clinical success. Here, KRAS is linked to non-small cell lung carcinoma.